drugset / Trial / NCT00039416
Imatinib Mesylate in Treating Patients With Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have myelofibrosis. Imatinib mesylate may stop the growth of myelofibrosis by blocking certain enzymes necessary for cell growth.
Timeline
- Start
- 2002-04
- Primary completion
- 2007-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | Oral |